𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Successful therapy and regression of splenomegaly in a patient with myeloproliferative hypereosinophilic syndrome (MHES) treated with imatinib

✍ Scribed by Ridz, S.L.; Khan, D.A.

Book ID
119275727
Publisher
Elsevier Science
Year
2005
Tongue
English
Weight
25 KB
Volume
115
Category
Article
ISSN
1097-6825

No coin nor oath required. For personal study only.

πŸ“œ SIMILAR VOLUMES

Results of imatinib mesylate therapy in
Results of imatinib mesylate therapy in patients with refractory or recurrent acute myeloid leukemia, high-risk myelodysplastic syndrome, and myeloproliferative disorders
✍ Jorge Cortes; Francis Giles; Susan O'Brien; Deborah Thomas; Maher Albitar; Mary πŸ“‚ Article πŸ“… 2003 πŸ› John Wiley and Sons 🌐 English βš– 92 KB πŸ‘ 2 views

## Abstract ## BACKGROUND Imatinib mesylate is a selective tyrosine kinase inhibitor of c‐abl, bcr/abl, c‐kit, and platelet‐derived growth factor‐receptor (PDGF‐R). c‐kit is expressed in most patients with acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) and PDGF has been implicated

A critical appraisal of conventional and
A critical appraisal of conventional and investigational drug therapy in patients with hypereosinophilic syndrome and clonal eosinophilia
✍ Matko Kalac; Alfonso QuintΓ‘s-Cardama; Radovan Vrhovac; Hagop Kantarjian; Srdan V πŸ“‚ Article πŸ“… 2007 πŸ› John Wiley and Sons 🌐 English βš– 121 KB πŸ‘ 1 views

## Abstract Hypereosinophilic syndrome (HES) is a rare disorder characterized by persistent and marked eosinophilia, leading to end‐organ damage. Over the last decade, great progress has been made in unraveling the molecular basis of HES that has resulted in the characterization of specific genetic